Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis
NCT04747652 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2021-07-01
Summary
Dermatomyositis (DM) is a highly heterogeneous autoimmune disease characterized by rash and myasthenia. Beside these, respiratory involvement is one of the common complications of DM. Interstitial lung disease (ILD) occur in approximately 90% of patients with DM, part of them may manifest rapidly progressive-interstitial lung disease (rp-ILD), which progresses into respiratory failure that is difficult to correct and leads to death. Early identification of rp-ILD high risk group is of great significance to improve the prognosis of patients and to conduct following clinical studies. A simple, easy, convenient and reliable diagnostic tool has not yet acquired till now.
Conditions
- Dermatomyositis
- Respiratory Injury
Sponsors & Collaborators
-
National Natural Science Foundation of China
collaborator OTHER_GOV -
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-06-01
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- China
Study Locations
More Related Trials
-
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
NCT05488327 ·Status: UNKNOWN ·Phase: NA
-
Study of Skin Tumors in Tuberous Sclerosis
NCT00001975 ·Status: RECRUITING
-
Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis
NCT01858259 ·Status: UNKNOWN
-
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
NCT02945345 ·Status: RECRUITING
-
Platform Clinical Study for Conquering Scleroderma
NCT06195072 ·Status: RECRUITING ·Phase: PHASE2
-
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
NCT00573326 ·Status: UNKNOWN ·Phase: PHASE2
-
Plexin D1 as a Potential Biomarker inPM/DM
NCT05637931 ·Status: UNKNOWN
-
Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases
NCT01387035 ·Status: RECRUITING
-
A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
NCT04274257 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Morbidity and Mortality Follow Up for the Scleroderma Lung Study
NCT01762449 ·Status: COMPLETED
-
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
NCT07090226 ·Status: RECRUITING ·Phase: NA
-
Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis
NCT01840748 ·Status: UNKNOWN
-
Utility of Breath-holding Test in Systemic Sclerosis
NCT04484948 ·Status: COMPLETED ·Phase: NA
-
ADSCs Therapy in Patients With CTD-ILD
NCT06574581 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
NCT00764309 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
NCT01559129 ·Status: TERMINATED ·Phase: PHASE2
-
Immunosuppressant Combined With Pirfenidone in CTD-ILD
NCT04928586 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT04864886 ·Status: RECRUITING
-
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
NCT02370693 ·Status: COMPLETED ·Phase: PHASE2
-
Western Sweden Systemic Sclerosis Project
NCT07345052 ·Status: RECRUITING
-
Development and Prevention of Severe Heart Disease in Systemic Sclerosis
NCT01829126 ·Status: UNKNOWN
-
Longitudinal Spatial Frequency Domain Imaging Study
NCT05672992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Microvascular and Fibrosis Imaging Study
NCT01758250 ·Status: COMPLETED